Abstract | AIM: METHODS AND RESULTS: Mice were subjected to 30 min ischaemia via ligation of the left main coronary artery to induce MI and either placebo or riociguat (1.2 µmol/l) were given as a bolus 5 min before and 5 min after onset of reperfusion. After 24 hours, both, late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) and (18)F-FDG-positron emission tomography (PET) were performed to determine infarct size. In the riociguat-treated mice, the resulting infarct size was smaller (8.5 ± 2.5% of total LV mass vs. 21.8% ± 1.7%. in controls, p = 0.005) and LV systolic function analysed by MRI was better preserved (60.1% ± 3.4% of preischaemic vs. 44.2% ± 3.1% in controls, p = 0.005). After 28 days, LV systolic function by echocardiography treated group was still better preserved (63.5% ± 3.2% vs. 48.2% ± 2.2% in control, p = 0.004). CONCLUSION: Taken together, mice treated acutely at the onset of reperfusion with the sGC stimulator riociguat have smaller infarct size and better long-term preservation of LV systolic function. These findings suggest that sGC stimulation during reperfusion therapy may be a powerful therapeutic treatment strategy for preventing post-MI heart failure.
|
Authors | Carmen Methner, Guido Buonincontri, Chou-Hui Hu, Ana Vujic, Axel Kretschmer, Stephen Sawiak, Adrian Carpenter, Johannes-Peter Stasch, Thomas Krieg |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 12
Pg. e83910
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 24391843
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Pyrazoles
- Pyrimidines
- Receptors, Cytoplasmic and Nuclear
- Guanylate Cyclase
- Soluble Guanylyl Cyclase
- riociguat
|
Topics |
- Animals
- Biomarkers
(analysis)
- Echocardiography
- Guanylate Cyclase
(metabolism)
- Heart Failure
(metabolism, pathology, prevention & control)
- Hemodynamics
(drug effects)
- Image Processing, Computer-Assisted
- Magnetic Resonance Imaging
- Male
- Mice
- Mice, Inbred C57BL
- Myocardial Infarction
(metabolism, pathology, prevention & control)
- Myocardial Reperfusion Injury
(metabolism, pathology, prevention & control)
- Positron-Emission Tomography
- Pyrazoles
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Receptors, Cytoplasmic and Nuclear
(metabolism)
- Soluble Guanylyl Cyclase
|